Select Publications
Books
2007, The extent of diversion of fentanyl for non-medical puposes in Australia: What do we know?, National Drug & Alcohol Research Centre, Randwick, NSW
,Book Chapters
2020, 'Opioids', in Geddes JR; Andreasen NC; Goodwin GM (ed.), New Oxford Textbook of Psychiatry, Oxford University Press, pp. 507 - 518, http://dx.doi.org/10.1093/med/9780198713005.003.0051
,Journal articles
2024, '96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104390
,2024, 'SMART Family and Friends: Feasibility and outcomes of a video-conference delivered intervention for families impacted by another's methamphetamine use.', J Subst Use Addict Treat, 161, pp. 209355, http://dx.doi.org/10.1016/j.josat.2024.209355
,2024, 'Health utility among people who regularly use opioids in Australia', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13823
,2023, 'The benefits and challenges of virtual SMART recovery mutual-help groups: Participant and facilitator perspectives', International Journal of Drug Policy, 120, http://dx.doi.org/10.1016/j.drugpo.2023.104174
,2023, 'Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies', The Lancet Psychiatry, 10, pp. 386 - 402, http://dx.doi.org/10.1016/S2215-0366(23)00095-0
,2023, 'The effectiveness of psychosocial interventions for family members impacted by another's substance use: A systematic review and meta-analysis', Drug and Alcohol Review, 42, pp. 960 - 977, http://dx.doi.org/10.1111/dar.13607
,2023, 'Supporting people affected by problematic alcohol, substance use and other behaviours under pandemic conditions: A pragmatic evaluation of how SMART recovery Australia responded to COVID-19', Addictive Behaviors, 139, http://dx.doi.org/10.1016/j.addbeh.2022.107577
,2023, 'Comorbid eating disorders among women receiving treatment for substance use disorders: a systematic review and meta-analysis', Addiction Research and Theory, 31, pp. 114 - 126, http://dx.doi.org/10.1080/16066359.2022.2127692
,2023, 'Online SMART Recovery mutual support groups: Characteristics and experience of adults seeking treatment for methamphetamine compared to those seeking treatment for other addictive behaviours', Drug and Alcohol Review, 42, pp. 20 - 26, http://dx.doi.org/10.1111/dar.13544
,2022, 'Opioid agonist treatment for people who are dependent on pharmaceutical opioids', Cochrane Database of Systematic Reviews, 2022, http://dx.doi.org/10.1002/14651858.CD011117.pub3
,2022, 'Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce', Drug and Alcohol Review, 41, pp. 1367 - 1390, http://dx.doi.org/10.1111/dar.13504
,2022, 'Eating Disorder Behaviours and Substance Use in Women Attending Treatment for Substance Use Disorders: a Latent Class Analysis', International Journal of Mental Health and Addiction, 20, pp. 2006 - 2023, http://dx.doi.org/10.1007/s11469-021-00497-z
,2022, 'Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain', International Journal of Drug Policy, 105, http://dx.doi.org/10.1016/j.drugpo.2022.103708
,2022, 'Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients', Drug and Alcohol Review, 41, pp. 841 - 850, http://dx.doi.org/10.1111/dar.13437
,2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100, http://dx.doi.org/10.1016/j.drugpo.2021.103492
,2022, 'Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103472
,2021, 'Preliminary psychometric evaluation of the patient reported experience measure for addiction treatment (PREMAT)', Addictive Behaviors, 123, http://dx.doi.org/10.1016/j.addbeh.2021.107048
,2021, 'SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups', Journal of Substance Abuse Treatment, 131, http://dx.doi.org/10.1016/j.jsat.2021.108568
,2021, 'Feasibility of a mobile health app for routine outcome monitoring and feedback in SMART recovery mutual support groups: Stage 1 mixed methods pilot study', Journal of Medical Internet Research, 23, http://dx.doi.org/10.2196/25217
,2021, 'Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study', British Journal of Clinical Pharmacology, 87, pp. 3092 - 3104, http://dx.doi.org/10.1111/bcp.14715
,2021, 'The use of Australian SMART Recovery groups by people who use methamphetamine: Analysis of routinely-collected nationwide data', Drug and Alcohol Dependence, 225, http://dx.doi.org/10.1016/j.drugalcdep.2021.108814
,2021, 'Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities', Addiction, 116, pp. 1482 - 1494, http://dx.doi.org/10.1111/add.15297
,2021, 'Facilitators and barriers to integrating physical health care during treatment for substance use: A socio-ecological analysis', Drug and Alcohol Review, 40, pp. 607 - 616, http://dx.doi.org/10.1111/dar.13197
,2021, 'Routine outcome measurement in specialist non-government alcohol and other drug treatment services: Establishing effectiveness indicators for the NADAbase', Drug and Alcohol Review, 40, pp. 540 - 552, http://dx.doi.org/10.1111/dar.13191
,2021, 'Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults with Chronic Noncancer Pain, 2012-2018', JAMA Network Open, 4, http://dx.doi.org/10.1001/jamanetworkopen.2021.3059
,2021, 'Characteristics and circumstances of death related to buprenorphine toxicity in Australia', Drug and Alcohol Dependence, 218, http://dx.doi.org/10.1016/j.drugalcdep.2020.108360
,2020, 'Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study', EClinicalMedicine, 28, http://dx.doi.org/10.1016/j.eclinm.2020.100592
,2020, 'Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: Protocol for the CoLAB study', BMJ Open, 10, pp. e034389, http://dx.doi.org/10.1136/bmjopen-2019-034389
,2020, 'Feasibility of a mobile health app for routine outcome monitoring and feedback in mutual support groups coordinated by SMART recovery Australia: Protocol for a pilot study', JMIR Research Protocols, 9, http://dx.doi.org/10.2196/15113
,2020, 'Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia', Addiction, 115, pp. 1295 - 1305, http://dx.doi.org/10.1111/add.14941
,2020, 'Substance Use and Co-occurring Physical Health Problems: File Review of a Residential Drug and Alcohol Treatment Service', Journal of Dual Diagnosis, 16, pp. 250 - 259, http://dx.doi.org/10.1080/15504263.2019.1704960
,2020, 'Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain', Drug and Alcohol Review, 39, pp. 128 - 134, http://dx.doi.org/10.1111/dar.13021
,2020, 'Health care engagement behaviors of men who use performance- and image-enhancing drugs in Australia', Substance Abuse, 41, pp. 139 - 145, http://dx.doi.org/10.1080/08897077.2019.1635954
,2020, 'Development of a brief patient-administered screening tool for prescription opioid dependence for primary care settings', Pain Medicine (United States), 21, pp. E79 - E88, http://dx.doi.org/10.1093/pm/pnz213
,2020, 'Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study.', Drug Alcohol Depend, 206, pp. 107697, http://dx.doi.org/10.1016/j.drugalcdep.2019.107697
,2019, 'Antidepressant Use among People Prescribed Opioids for Chronic Noncancer Pain', Pain Medicine (United States), 20, pp. 2450 - 2458, http://dx.doi.org/10.1093/pm/pnz009
,2019, 'Circumstances of death of opioid users being treated with naltrexone', Addiction, 114, pp. 2000 - 2007, http://dx.doi.org/10.1111/add.14729
,2019, 'Regulatory and other responses to the pharmaceutical opioid problem', Medical Journal of Australia, 211, pp. 237 - 237.e1, http://dx.doi.org/10.5694/mja2.50303
,2019, 'A protocol for a discrete choice experiment: Understanding patient medicine preferences for managing chronic non-cancer pain', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2018-027153
,2019, 'Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study (Preprint)', , http://dx.doi.org/10.2196/preprints.15113
,2019, 'Concerns and help-seeking among patients using opioids for management of chronic noncancer pain', Pain Medicine (United States), 20, pp. 758 - 769, http://dx.doi.org/10.1093/pm/pny078
,2019, 'A population-based study of transdermal fentanyl initiation in Australian clinical practice', European Journal of Clinical Pharmacology, 75, pp. 401 - 408, http://dx.doi.org/10.1007/s00228-018-2588-0
,2019, 'Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations', Addiction, 114, pp. 404 - 405, http://dx.doi.org/10.1111/add.14556
,2019, 'Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting', Addiction, 114, pp. 389 - 399, http://dx.doi.org/10.1111/add.14380
,2019, 'Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007–2015', Drug and Alcohol Review, 38, pp. 159 - 168, http://dx.doi.org/10.1111/dar.12908
,2019, 'Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study', Pharmacoepidemiology and Drug Safety, 28, pp. 97 - 105, http://dx.doi.org/10.1002/pds.4683
,2019, 'Regulatory and other responses to the pharmaceutical opioid problem', Medical Journal of Australia, 210, http://dx.doi.org/10.5694/mja2.12047
,2018, 'Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 887 - 896, http://dx.doi.org/10.1111/dar.12859
,